» Authors » Javier Perez-Calvo

Javier Perez-Calvo

Explore the profile of Javier Perez-Calvo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 204
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrone P, Perez-Calvo J, Brathwaite C, Islam S, Joseph D
Int J Surg . 2019 Dec; 74:13-21. PMID: 31870753
Background: Traumatic kidney injury is an infrequent event with a wide range of injury patterns. The aim of this paper is to review the incidence, mechanisms of injury, diagnostic methods,...
2.
DAvola D, Fernandez-Ruiz V, Carmona-Torre F, Mendez M, Perez-Calvo J, Prosper F, et al.
Transl Res . 2016 Mar; 188:80-91.e2. PMID: 26972567
The aim of this nonrandomized, open label, phase 1 clinical trial was to evaluate the safety and the feasibility of the treatment with autologous bone marrow-derived endothelial progenitor cells (EPC)...
3.
Arranz R, Garcia-Noblejas A, Grande C, Cannata-Ortiz J, Sanchez J, Garcia-Marco J, et al.
Haematologica . 2013 Jun; 98(10):1563-70. PMID: 23753021
Unlabelled: The prognosis for fit patients with mantle cell lymphoma has improved with intensive strategies. Currently, the role of maintenance/consolidation approaches is being tested as relapses continue to appear. In...
4.
Alfaro C, Perez-Gracia J, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, et al.
J Immunol . 2011 Nov; 187(11):6130-42. PMID: 22048768
Twenty-four patients with metastatic cancer received two cycles of four daily immunizations with monocyte-derived dendritic cells (DC). DC were incubated with preheated autologous tumor lysate and subsequently with IFN-α, TNF-α,...
5.
Nieto Y, Aldaz A, Rifon J, Perez-Calvo J, Zafra A, Zufia L, et al.
Biol Blood Marrow Transplant . 2007 Oct; 13(11):1324-37. PMID: 17950919
The purpose of this trial was to define the maximum tolerated duration (MTD), dose-limiting toxicity (DLT), regimen-related toxicities (RRT), and pharmacokinetics of gemcitabine infused at a fixed dose rate (FDR)...
6.
Inoges S, Rodriguez-Calvillo M, Zabalegui N, Lopez-Diaz de Cerio A, Villanueva H, Soria E, et al.
J Natl Cancer Inst . 2006 Sep; 98(18):1292-301. PMID: 16985248
Background: Follicular lymphoma is considered incurable, although cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy can induce sequential remissions. A patient's second complete response is typically shorter than that patient's first...
7.
Rubia J, Blade J, Lahuerta J, Ribera J, Martinez R, Alegre A, et al.
Haematologica . 2006 Apr; 91(5):621-7. PMID: 16627253
Background And Objectives: Although alkylating agents are clearly beneficial in multiple myeloma (MM), their deleterious effect on bone marrow hematopoietic progenitor cells usually precludes their use as front-line therapy in...
8.
Andreu E, Lledo E, Poch E, Ivorra C, Albero M, Martinez-Climent J, et al.
Cancer Res . 2005 Apr; 65(8):3264-72. PMID: 15833859
Chronic myelogenous leukemia (CML) is characterized by the expression of the BCR-ABL tyrosine kinase, which results in increased cell proliferation and inhibition of apoptosis. In this study, we show in...
9.
Zabalegui N, Lopez-Diaz de Cerio A, Inoges S, Rodriguez-Calvillo M, Perez-Calvo J, Hernandez M, et al.
Haematologica . 2004 May; 89(5):541-6. PMID: 15136216
Background And Objectives: Among B-cell malignancies, follicular lymphomas (FL) more frequently show acquired, potential N-glycosylation sites (AGS) within tumor-specific immunoglobulin. The aim of this study was to extend this observation...
10.
Inoges S, Rodriguez-Calvillo M, Lopez-Diaz de Cerio A, Zabalegui N, Perez-Calvo J, Panizo C, et al.
Haematologica . 2003 Dec; 88(12):1438-40. PMID: 14688006
No abstract available.